ATLANTA—A recently approved diagnostic assay may improve clinicians’ ability to predict a prostate cancer patient’s risk of clinical recurrence after radical prostatectomy (RP), a company announced at the American Urological Association 2012 annual meeting.
The Nucleic Acid Detection Immunoassay, which is marketed by Iris International as NADiA ProsVue, determines the rate of change of serum total PSA over a period of time. Results are calculated as the linear slope of three ProsVue total PSA test results obtained on three serum samples collected between six weeks and 20 months post-RP.
The ProsVue technology was validated through a retrospective clinical study of more than 300 patients, according to Jonathan E. McDermed, PharmD, Director of Scientific & Clinical Affairs for Iris Molecular Diagnostics. Among the patients that the assay identified as having a decreased risk for clinical recurrence, 92.7% showed no signs of clinical recurrence. For patients identified as not being at reduced risk, 78% ultimately showed clinical recurrence.